| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Research and development | 74,536 | 70,471 | ||
| Selling, general and administrative | 22,280 | 23,103 | ||
| Total operating expenses | 96,816 | 93,574 | ||
| Revenue | NaN | 93 | ||
| Cost of goods sold | NaN | 50 | ||
| Gross profit | NaN | 43 | ||
| Loss from operations | -96,816 | -93,531 | ||
| Interest income, net | 1,540 | 4,146 | ||
| Change in fair value of notes payable | 4,724 | -2,830 | ||
| Change in fair value of warrant liabilities | 40,901 | -17,908 | ||
| Other expense, net | -53 | -47 | ||
| Total other income (expense), net | -44,138 | 24,837 | ||
| Net loss and comprehensive loss | -140,954 | -68,694 | ||
| Accretion of dividends on convertible preferred stock | NaN | 1,737 | ||
| Net loss attributable to common stockholders | -140,954 | -70,431 | ||
| Basic EPS | -1.86 | -1.62 | ||
| Diluted EPS | -1.86 | -1.62 | ||
| Basic Average Shares | 75,819,960 | 43,541,527 | ||
| Diluted Average Shares | 75,819,960 | 43,541,527 | ||
FRACTYL HEALTH, INC. (GUTS)
FRACTYL HEALTH, INC. (GUTS)